Article Details
Retrieved on: 2022-08-19 07:29:36
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Invex Therapeutics (ASX: IXC) will begin a phase III clinical trial of its drug Presendin after locking-in approval along with investigational new ...
Article found on: smallcaps.com.au
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here